Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06547229
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
None
First Post:
2024-08-07
Brief Title:
Clinicopathological Features and Genetic Susceptibility Screening of Recurrent Drug-induced Liver Injury
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Clinicopathological Features and Genetic Susceptibility Screening of Recurrent Drug-induced Liver Injury
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RDILI-GS
Brief Summary:
The goal of this observational study is to screening for clinical pathological and HLA features in patients with recurrent drug-induced liver injury The main question it aims to answer is Which patients with drug-induced liver injury need to be more cautious when re-dosing
Detailed Description:
Research Objectives
1 To summarise the clinicopathological characteristics of patients with recurrent drug-induced liver injury DILI in the Liver Disease Centre of Beijing Friendship Hospital in the past 10 years
2 Compare the differences in clinicopathological characteristics between patients with only one episode of different drug use and those with recurrent DILI and predict the riskprotective factors in patients with recurrent DILI
3 Explore the susceptibility genes in patients with recurrent DILI
1 To summarise the clinicopathological characteristics of patients with recurrent drug-induced liver injury DILI in the Liver Disease Centre of Beijing Friendship Hospital in the past 10 years
2 Compare the differences in clinicopathological characteristics between patients with only one episode of different drug use and those with recurrent DILI and predict the riskprotective factors in patients with recurrent DILI
3 Explore the susceptibility genes in patients with recurrent DILI
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None